MyoKardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease. The company's proprietary platform combines recent breakthroughs in muscle biology with leading-edge cardiovascular disease genetics. This personalized, genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically improve the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure. Founded by world leaders in muscle biology and cardiovascular disease genetics, MyoKardia was launched in 2012 with funding from leading life sciences investor, Third Rock Ventures
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/20/12 | $38,000,000 | Series A |
Third Rock Ventures | undisclosed |
